Combination therapy comprising sglt inhibitors and dpp4 inhibitors
AssigneeMitsubishi Tanabe Pharma Corporation
InventorsKiichiro Ueta, Kenji Arakawa, Yasuaki Matsushita
Life of this patent
Estimating the term…
Abstract
The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the combination is useful for prevention or treatment of conditions such as diabetes and diseases related to diabetes.
Claims30
A method for treating or preventing diabetes or a condition related to diabetes comprising administering to a patient in need thereof a therapeutically effective amount of an SGLT inhibitor and a DPP4 inhibitor.
A method for preventing or treating a disease which is associated with plasma active GLP-1 level comprising administering to a patient in need thereof a therapeutically effective amount of an SGLT inhibitor and a DPP4 inhibitor.
A method for increasing plasma active GLP-1 level comprising administering to a patient a therapeutically effective amount of an SGLT inhibitor and a DPP4 inhibitor.
A pharmaceutical composition comprising an SGLT inhibitor, a DPP4 inhibitor and a pharmaceutically acceptable carrier or diluent, wherein the SGLT inhibitor and the DPP4 inhibitor are in amounts sufficient to increase plasma active GLP-1 level in a patient.
Use of an SGLT inhibitor in combination with a DPP4 inhibitor as active ingredients for manufacture of a pharmaceutical preparation for treating or preventing a disease associated with plasma active GLP-1 level.
A product containing an SGLT inhibitor and a DPP4 inhibitor as a combined preparation for simultaneous, separate or sequential administration for preventing or treating a disease associated with plasma active GLP-1 level.
Dependencies are inferred from the claim text.